Madrigal Pharmaceuticals
$499.40Change from previous close: −0.06%Absolute change: −$0.31
At a glance
- Revenue growth
- +432.05%
- 2025 vs 2024
- Net margin
- -30.1%
- 2024: -258.6%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating cash flow | -190 | -456 | -324 | -225 |
| Depreciation and amortization | 1.5 | 1.1 | 0.5 | 0.5 |
| Capital expenditure | -3.5 | -6.5 | -1.5 | -0.2 |
| Investing cash flow | 32.3 | -274 | -503 | 207 |
| Financing cash flow | 256 | 735 | 595 | 313 |
| Debt issued | 350 | 0.0 | 65.0 | 50.0 |
| Debt repaid | -122 | 0.0 | 0.0 | — |
| Effect of exchange rates | 0.0 | 0.0 | 0.0 | — |
| Net change in cash | 98.8 | 5.1 | -232 | 295 |
| Free cash flow | -193 | -462 | -326 | -225 |